References
1. P. B. Lockhart and Y. Sun, “Diseases of the cardiovascular system,” Burket’s Oral Med., pp. 505–552, 2021.
2. P. Kasper et al., “NAFLD and cardiovascular diseases: a clinical review,” Clin. Res. Cardiol., vol. 110, no. 7, pp. 921–937, 2021.
3. H. E. Bays, “Ten things to know about ten cardiovascular disease risk factors (‘ASPC Top Ten–2020’),” Am. J. Prev. Cardiol., vol. 1, p. 100003, 2020.
4. X. Fu, Q. Liu, X. Zeng, S. Huang, R. Huang, and Q. Gao, “Association between cerebral arterial stiffness and large artery atherosclerosis in acute ischemic stroke,” J. Stroke Cerebrovasc. Dis., vol. 27, no. 11, pp. 2993–3000, 2018.
5. P. Libby et al., “Lewis EF,” Atheroscler. Nat. Rev. Dis. Prim., vol. 5, no. 1, p. 56, 2019.
6. C. Cayrol and J. Girard, “Interleukin‐33 (IL‐33): a nuclear cytokine from the IL‐1 family,” Immunol. Rev., vol. 281, no. 1, pp. 154–168, 2018.
7. M. W. Dahlgren et al., “Adventitial stromal cells define group 2 innate lymphoid cell tissue niches,” Immunity, vol. 50, no. 3, pp. 707–722, 2019.
8. P. Raggi et al., “Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions,” Atherosclerosis, vol. 276, pp. 98–108, 2018.
9. A. Anfray et al., “Single-and two-chain tissue-type plasminogen activator treatments differentially influence cerebral recovery after stroke,” Exp. Neurol., vol. 338, p. 113606, 2021.
10. R. B. Alsina and L. I. Mukhametova, “Structure and function of plasminogen/plasmin system,” Russ. J. Bioorganic Chem., vol. 40, no. 6, pp. 590–605, 2014.
11. P. Jirak et al., “A Comparative Analysis of Novel Biomarkers in Sepsis and Cardiovascular Disease,” Appl. Sci., vol. 12, no. 3, p. 1419, 2022.
12. G. Isola, A. Polizzi, A. Alibrandi, R. C. Williams, and R. Leonardi, “Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase‐type plasminogen activator receptor (suPAR) levels,” J. Periodontol., vol. 92, no. 6, pp. 896–906, 2021.
13. F. Napolitano and N. Montuori, “The role of the plasminogen activation system in angioedema: Novel insights on the pathogenesis,” J. Clin. Med., vol. 10, no. 3, p. 518, 2021.
14. M. C. Drinane, J. A. Sherman, A. E. Hall, M. Simons, and M. J. Mulligan‐Kehoe, “Plasminogen and plasmin activity in patients with coronary artery disease,” J. Thromb. Haemost., vol. 4, no. 6, pp. 1288–1295, 2006.
15. A. G. Bharadwaj, R. W. Holloway, V. A. Miller, and D. M. Waisman, “Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy,” Cancers (Basel)., vol. 13, no. 8, p. 1838, 2021.
16. Y. Shen, “Plasminogen: a novel inflammatory regulator that promotes wound healing.” Umeå University, 2013.
17. Tuama, A. N., Abbas, K. H., Hamzah, M. Q., Jabbar, A. H., & Agam, M. A. (2020). An Overview on Characterization of Silver/Cuprous Oxide Nanometallic (Ag/Cu2O) As Visible Light Photocatalytic. International Journal of Advanced Science and Technology, 29(03), 5008-5018.
18. Mezan, S. O., Jabbar, A. H., Hamzah, M. Q., Tuama, A. N., Hasan, N. N., & Agam, M. A. (2018). Synthesis and Characterization of Zinc Sulphide (ZnS) Thin Film Nanoparticle for Optical Properties. Journal of Global Pharma Technology, 10(07), 369-373.
19. L. J. H. Rasmussen, J. E. V. Petersen, and J. Eugen-Olsen, “Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation,” Front. Immunol., vol. 12, 2021.
20. H. Enocsson et al., “Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus,” J. Autoimmun., vol. 106, p. 102340, 2020.
21. T. Skalec, B. Adamik, K. Kobylinska, and W. Gozdzik, “Soluble Urokinase-Type Plasminogen Activator Receptor Levels as a Predictor of Kidney Replacement Therapy in Septic Patients with Acute Kidney Injury: An Observational Study,” J. Clin. Med., vol. 11, no. 6, p. 1717, 2022.
22. M. Persson, G. Engström, H. Björkbacka, and B. Hedblad, “Soluble urokinase plasminogen activator receptor in plasma is associated with the incidence of CVD. Results from the Malmö Diet and Cancer Study,” Atherosclerosis, vol. 220, no. 2, pp. 502–505, 2012.
23. D. J. Eapen et al., “Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and future adverse events,” J. Am. Heart Assoc., vol. 3, no. 5, p. e001118, 2014.
24. S. Botha, C. M. T. Fourie, R. Schutte, J. Eugen-Olsen, R. Pretorius, and A. E. Schutte, “Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population,” Int. J. Cardiol., vol. 184, pp. 631–636, 2015.
25. J. Chew-Harris, S. Appleby, A. M. Richards, R. W. Troughton, and C. J. Pemberton, “Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals,” Clin. Biochem., vol. 69, pp. 36–44, 2019.